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Abstract Genetic polymorphism of X-ray repair
crosscomplementing group 3 (XRCC3 ) Thr241Met has been
implicated to alter the risk of ovarian cancer, but the results are
controversial. In order to get a more precise result, a meta-
analysis was performed. All eligible studies were identified
through an extensive search in PubMed, Excerpta Medica
Database (Embase), Chinese National Knowledge Infrastruc-
ture database, and Chinese Biomedical Literature Database
before August 2013. The association between the XRCC3
Thr241Met polymorphism and ovarian cancer risk was con-
ducted by odds ratios (ORs) and 95 % confidence intervals
(95 % CIs). Finally, a total of four publications including
seven studies with 3,635 cases and 5,473 controls were in-
cluded in our meta-analysis. Overall, there was no association
between XRCC3 Thr241Met polymorphism and risk of ovar-
ian cancer under all five genetic models in overall population
(T vs. C: OR=0.99, 95 % CI=0.960–1.03, P =0.752; TT vs.
CC: OR=1.00, 95 % CI=0.91–1.10, P =0.943; TC vs. TT:
OR=0.97, 95 % CI=0.92–1.04, P =0.396, Fig. 1; TT vs. TC/
CC: OR=1.00, 95 % CI=0.91–1.12, P =0.874; TT/TC vs.
CC: OR=0.98, 95 % CI=0.94–1.03, P =0.486). In the sub-
group analysis according to ethnicity, the results suggested
that XRCC3 Thr241Met polymorphism was not associated
with the risk of ovarian cancer in Caucasians population. No
significant association was found between the XRCC3 Thr241
Met polymorphism and the risk of ovarian cancer. Given the
limited sample size and ethnicities included in the meta-
analysis, further large scaled and well-designed studies are
needed to confirm our results.
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Introduction
Ovarian cancer is the eighth most commonly diagnosed can-
cer and the fifth leading cause of cancer death in the females
worldwide with an estimated 225,500 new cases and 140,200
deaths every year [1, 2]. Though there are many advances in
the classification, diagnosis, and treatment of ovarian cancer,
it is still difficult to diagnose early and causes serious damage
to public health [3, 4]. Since the low rate of early detection, the
late clinical manifestation, and the lack of effective treatments,
the 5-year survival rate for ovarian cancer patients is only
about 40 % [1]. What is worse, the mechanism of ovarian
carcinogenesis is not unclear yet, and multiple factors may
increase the risk of developing ovarian cancer, such as age,
gravidity, tubal ligation, number of ovulatory cycles, family
history of ovarian cancer as well as lifestyle factors [3, 5].
However, not all of those who expose to those risk factors
develop ovarian cancer, which suggests genetic factors may
also play an important role in the host’s susceptibility to
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ovarian cancer [6]. Candidate genes include the insulin recep-
tor substrate 1 [7], lysyl oxidase G473A [8], vitamin D recep-
tor [9], and MTHFR C677T [2].
Another candidate gene that has received a lot of attention is
the X-ray repair cross-complementing group 3(XRCC3 ).
XRCC3 , located at chromosome 14q32.3, is a member of
DNA repair genes and involved in maintaining the stability of
genome by homologous recombination repair for DNAdouble-
strand breaks [10, 11]. The Thr241Met is the most common
polymorphism of XRCC3 , which substitutes at codon 241 in
exon 7, with a C to T transition (XRCC3-18067C/T, rs861539)
[11, 12]. We called this SNP in the XRCC3 gene “-18067C/T”
for short in this meta-analysis. Previous studies were performed
to investigate the relationship between the XRCC3-18067C/T
polymorphism and ovarian cancer risk [13–16]. However, the
results were controversial, which might be caused by the lim-
itation of individual studies. To assess the association between
XRCC3 -18067C/T polymorphism and ovarian cancer risk
more precisely, we conducted a meta-analysis.
Materials and methods
Search strategy
To identify all currently available studies on the association
between XRCC3-18067C/T polymorphism and ovarian can-
cer risk, we conducted an extensive search in PubMed,
Excerpta Medica Database (Embase), Chinese National
Knowledge Infrastructure database, and Chinese Biomedical
Literature Database before August 2013 by using the terms as
follows: “XRCC3” or “X-ray cross complementing group 3”
in combination with “polymorphism,” “polymorphisms,”
“variant,” or “mutation” in combination with “ovarian can-
cer,” “ovarian carcinoma,” or “ovarian tumor” for all publica-
tions. There was no language limitation. Additional studies
were identified by a hand search of the references of original
studies. Review articles were also examined to find more
eligible studies.
Inclusion and exclusion criteria
Studies to be included in the meta-analysis were required to
meet the following criteria: (a) it assessed the association
between the XRCC3 -18067C/T polymorphism and ovarian
cancer, (b) a case–control design, (c) the genotype distribution
among the control population was consistent with Hardy–
Weinberg Equilibrium (HWE), and (d) sufficient reported
genotypic frequencies in both cases and controls for estimat-
ing an odds ratio (OR) with its 95% confidence interval (95%
CI). The following exclusion criteria were used for excluding
studies: (a) control population including patients, (b) studies
contained duplicate data, and (c) case reports or reviews.
Data extraction
Information was carefully extracted from all eligible publica-
tions by two authors independently according to the inclusion
criteria listed above, disagreements were resolved through
consensus, if could not reached agreement, another author
was consulted to resolve the debate. The following informa-
tion was extracted: the name of first author, year of publica-
tion, country of origin, ethnicity of the population, genotyping
methods, source of the control group, sample size of cases.
Different ethnicities were categorized as Caucasians and
mixed.
Statistical analysis
The possible association between the XRCC3 -18067C/T
polymorphism and ovarian cancer susceptibility was mea-
sured by the pooled ORs with corresponding 95 % CIs in five
genetic models: allele contrast (T vs. C), homozygote (TT vs.
CC), heterozygote (TC vs. CC), recessive (TT vs. TC/ CC),
and dominant (TT/TC vs. CC) models, respectively. Hetero-
geneity was checked by the Chi-square based Q statistic. If the
result of the heterogeneity test P <0.10, suggested the
between-study heterogeneity was existed, ORs were pooled
by random-effects model (DerSimonian and Laird method)
[17]. Otherwise, the fixed-effects model (theMantel-Haenszel
method) was used [18]. In addition, the effect of heterogeneity
was quantified also by using I2 value [19]. If obvious hetero-
geneity existed (I2value >50 % or P <0.10), the overall esti-
mate of risk was calculated by the random-effects model;
when obvious heterogeneity was absent, the fixed-effects
model was used.
The HWE was assessed by using a professional web-based
program (http://ihg2.helmholtz-muenchen.de/cgibin/hw/
hwa1.pl) to confirm whether the genotype distribution of
XRCC3-18067C/T in controls agreed with HWE if P >0.05
suggests the controls followed HWE balance. Egger’s linear
regression test was applied to examine the possible publica-
tion bias, Egger’s test (P <0.05 was considered representative
of statistically significant publication bias) [20]. Publication
bias was also tested by visual observation of funnel plot [21].
Statistical analysis was undertaken using the program STATA




After carefully selecting based on the search criteria above, a
total of four publications including seven studies with 3,635
cases and 5,473 controls were included in our meta-analysis
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[13–16], all of these publications were written in English.
There were six studies of Caucasians and one mixed. The
genotype distribution in the controls of all the studies included
in the meta-analysis were consistent with HWE (all P >0.05).
The study characteristics included in the meta-analysis were
listed in Table 1.
Quantitative synthesis of data
The main results of the meta-analysis were listed in Table 2.
Meta-analysis of the total studies showed that there was no
association between XRCC3 Thr241Met polymorphism and
risk of ovarian cancer under all five genetic models in overall
population (T vs. C: OR=0.99, 95 % CI=0.96–1.03,
P =0.752; TT vs. CC: OR=1.00, 95 % CI=0.91–1.10,
P =0.943; TC vs. TT: OR=0.97, 95 % CI=0.92–1.04,
P =0.396, Fig. 1; TT vs. TC/CC: OR=1.00, 95 % CI=0.91–
1.12, P =0.874; TT/TC vs. CC: OR=0.98, 95 % CI=0.94–
1.03, P =0.486). In the subgroup analysis according to ethnic-
ity, the results suggested that XRCC3 Thr241Met polymor-
phism was not associated with the risk of ovarian cancer in
Caucasians population (only shown homozygote model in
Fig. 2). Detailed data are shown in Table 2.
Heterogeneity analysis and publication bias analysis
There was a significant heterogeneity found under heterozy-
gote (TC vs. CC) and dominant (TT/TC vs. CC) genetic
models in overall population. To examine the source of het-
erogeneity, we assessed the dominant model (TT/TC vs. CC)
by ethnicity. However, the results showed there was no obvi-
ous heterogeneity in the subgroup analyses of both Caucasians
and mix, suggesting that ethnicity was the major source of
heterogeneity in our meta-analysis.
Funnel plot and Egger’s test were used to assess the publi-
cation bias in this meta-analysis. Funnel plot is relatively
Table 1 General characteristics of studies included in the meta-analysis
First author Year Country Ethnicity Method of genotyping Source of control Sample size (case control) HWE of control
Auranen(a) 2005 UK Caucasian TaqMan PB 1139/1614 0.395
Auranen(b) 2005 USA Caucasian TaqMan PB 270/344 0.111
Auranen(c) 2005 Danish Caucasian TaqMan PB 361/891 0.080
Hormazabal 2012 Chile Mix TaqMan PB 87/570 0.172
Beesley(a) 2007 Australia Caucasian PCR-RFLP PB 504/972 0.326
Beesley(b) 2007 Australia Caucasian PCR-RFLP PB 731/747 0.950
Webb 2005 Australia Caucasian PCR HB 543/335 0.420
PCR-RFLP PCR–restriction fragment length polymorphism, HWE Hardy–Weinberg equilibrium, HB hospital based, PB population based
Table 2 Results of meta-analysis
for XRCC3 Thr241Met polymor-
phism and ovarian cancer risk
OR odds ratio, CI confidence in-
terval, F fixed-effects model, R
random-effects model
Comparison Population N Test of association Model Test of heterogeneity
OR 95 % CI P value P value I2
T vs. C Overall 7 0.99 0.96–1.03 0.752 F 0.156 35.6
Mix 1 1.33 1.03–1.71 0.027 F – –
Caucasians 6 1.00 0.96–1.03 0.507 F 0.534 0
TT vs. CC Overall 7 1.00 0.91–1.10 0.943 F 0.111 42.0
Mix 1 2.83 1.43–4.91 5.62 F – –
Caucasians 6 0.98 0.89–1.08 0.658 F 0.933 0
TC vs. CC Overall 7 0.97 0.92–1.04 0.396 R 0.068 48.8
Mix 1 1.08 0.81–1.44 0.590 F – –
Caucasians 6 0.97 0.91–1.03 0.336 R 0.045 55.9
TT vs. TC/CC Overall 7 1.00 0.91–1.12 0.874 F 0.131 39.1
Mix 1 2.83 1.40–5.75 0.004 F – –
Caucasians 6 0.99 0.89–1.10 0.852 F 0.908 0
TT/TC vs. CC Overall 7 0.98 0.94–1.03 0.486 R 0.083 46.3
Mix 1 0.99 0.96–1.02 0.175 F – –
Caucasians 6 0.99 0.95–1.02 0.426 F 0.104 45.2
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straightforward to observe whether the presence of publication
bias and Egger’s test was provided statistical evidence of sym-
metries of the plots. As a result, both the shape of the funnel
plot and Egger’s test value did not suggest any evidence of
obvious asymmetry (Fig. 3, all P >0.05, data not shown).
Discussion
It is well known that SNPs are the most common sources of
human genetic variation, and they may contribute to an indi-
vidual’s susceptibility to cancer. XRCC3 plays a critical role in
maintaining genomic integrity by repairing radiation-induced
DNA double-strand breaks, and the XRCC3 polymorphism
may affect the DNA repair capacity of its encoded protein,
thus, contributes to the development of cancers [11, 12].
Since the identification of XRCC3 Thr241Met polymor-
phism, a growing number of studies suggested that XRCC3
Thr241Met polymorphism plays an important role in the
development of cancers, such as glioma [22], hepatocellular
carcinoma [23], head and neck cancer [24], lung cancer [25],
and so on. Many published studies that aim at the role of
XRCC3 Thr241Met polymorphism in ovarian cancer risk
have been performed, but the results are controversial. Differ-
ent study designs, various methodologies, and different pop-
ulation backgrounds would inevitably increase the risk, which
should be responsible for the controversial conclusions. How-
ever, meta-analysis is a powerful tool for analyzing cumula-
tive data of studies which the individual sample sizes are small
and the statistical power is low. No meta-analysis evaluating
on the association between the XRCC3 Thr241Met polymor-
phisms and ovarian cancer risk has been performed. So, we
carried out a meta-analysis.
A total of four publications including seven studies with 3,
635 cases and 5,473 controls were included in our meta-
analysis [13–16]. The results of the meta-analysis showed that
XRCC3 Thr241Met polymorphism was not associated with
ovarian cancer risk in the overall populations. Subgroup anal-
ysis based on ethnicity indicated that XRCC3 Thr241Met
polymorphism was not a risk factor for Caucasians, but is a
risk for mix. The results about mix may not be accurate
because only one study was found about mix; the sample size
is too small to explain the conclusion.
The heterogeneity is a very important part of a meta-
analysis, and finding the possible sources for the high hetero-
geneity is very important [26, 27]. The studies included in our
meta-analysis probably have different genetic backgrounds,
environmental exposures, methodology, and sample size,
thus, caused the inconsistent conclusions. In this study, obvi-
ous heterogeneity between-study was found under heterozy-
gote and dominant genetic models in the overall population.
To explore the possible sources for the heterogeneity in the
meta-analysis, we performed subgroup analysis by ethnicity.
Through subgroup analysis, we found that ethnicity was the
major source of the heterogeneity in our meta-analysis, which
Fig. 1 The forest plot describing the meta-analysis under heterozygous
model for the association between XRCC3 Thr241 Met polymorphism
and the risk of ovarian cancer in overall population (TC vs. CC)
Fig. 2 The forest plot describing the meta-analysis under homozygous
model for the association between XRCC3 Thr241 Met polymorphism
and the risk of ovarian cancer in Caucasians (TT vs. CC)
Fig. 3 Begg funnel plot for publication bias test for the association
between XRCC3 Thr241 Met polymorphism and the risk of ovarian
cancer under heterozygous model (TC vs. CC). Each point represents a
separate study for the indicated association. Log [OR] natural logarithm
of OR. Horizontal line means effect size
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could be explained by the race-specific effect of XRCC3
Thr241Met polymorphism and the susceptibility of ovarian
cancer that is because different countries may have different
genetic backgrounds and environmental exposures. Publica-
tion bias is another important factor which may have a nega-
tive effect on the meta-analysis. Both Funnel plot and Egger’s
test were used to assess the publication bias of our meta-
analysis. The shape of funnel plot and statistical results show
no obvious publication bias found; this indicates that the
publication bias has little effect on the results of our study,
and the results of our meta-analysis are relatively stable.
There are several limitations in our meta-analysis that should
be considered. Firstly, the sample sizes are relatively small; there
are only seven studies with a total of 3,635 cases and 5,473
controls included in our meta-analysis. More studies with large
sample size and well-designed are needed to further identify this
association more comprehensively. Secondly, studies included
in the present meta-analysis mainly provided data towards Cau-
casians in the light of the race-specific association probably
exist; other ethnicities including Asians, Africans, and others
should be investigated in future studies. Thirdly, subgroup anal-
yses according to age, radiation exposure, histological types, and
other elements have not been performed due to insufficient
relevant data available in the primary studies. Finally, only
published and English studies were included in this study; thus,
publication and potential language biases may occur.
In summary, our meta-analysis systematically analyzed the
association between XRCC3 Thr241Met polymorphism and
the risk of ovarian cancer. No significant association was
found between the XRCC3 Thr241 Met polymorphism and
the risk of ovarian cancer. Given the limited sample size and
ethnicities included in the meta-analysis, further larger scaled
and well-designed studies are needed to confirm our results.
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